KMT2A and acute myeloid leukemia: AML is a typically lethal molecularly heterogeneous disease, where MV4-11 is the most used AML cell line to determine drug efficacy, due to the cells bearing most common AML mutations such as FLT3-ITD, TP53, and MLL-AF4 fusion oncogene.